IP Library › Granted Patent US 8,440,176
Granted Patent B2
US 8,440,176 · App. 12/429,703 · Granted May 14, 2013

Covalently grafted pharmaceutically active polymers

Inventors: Frank Laronde (Toronto, CA); Fan Gu (Mississauga, CA)
Assignee: Interface Biologics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,176
App. No.
12/429,703
Granted
May 14, 2013
Kind
B2
Abstract

The invention relates to graftable polymers comprising biologically active agents and the use of such polymers in the manufacture of shaped articles, such as implantable medical devices and catheters. The graftable polymers are covalently grafted to a surface via one or more grafting moieties incorporated into the pharmaceutically-active graftable polymer. The coated articles of the invention can further comprise tie-coats, and the ratio of polymer:tie coat can be used to adjust the rate of drug elution.

Claims (21)

1. A graftable polymer having the following structure:

wherein

(i) each Bio is, independently, one or more biologically active agents or precursors thereof;

(ii) C1 is a coupling segment

(iii) C2 is a hydrolysable coupling segment or a polyamide linker susceptible to hydrolysis by a peptidase enzyme linking Bio to Bio;

(iv) Oligo comprises a repeating monomeric unit or units that number less than 50 monomeric units and has a molecular weight less than 5 KDa;

(v) G″ is a grafting moiety that has the following structure:

wherein, independently,

a. X is either —NH— or —O—;

b. m is an integer between 1 and 6;

c. n is an integer between 0 and 6; and

d. R is an optional substituent selected from —H; —NO 2 , or —CF 3 ;

wherein each of n, o, and p is independently an integer greater than 0, and

wherein G″ is covalently tethered to Bio, C1, C2, or Oligo.

2. The graftable polymer of claim 1 , wherein Bio comprises ciprofloxacin and/or chlorhexidine.

3. The graftable polymer of claim 1 , wherein G″ is

4. The graftable polymer of claim 3 , wherein

Bio is ciprofloxacin or chlorhexidine;

C1 comprises 2,2,4-trimethylhexamethylene diisocyanate (THDI);

Oligo comprises poly(ε-caprolactone) diol (PCL); and

5. The graftable polymer of claim 1 , wherein said graftable moiety requires photolytic or thermolytic activation for grafting to a polymer surface.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2020
From: INTERFACE BIOLOGICS INC.
To: RIPPLE THERAPEUTICS CORPORATION
Reel/Frame 051498/0758 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2013
From: LARONDE, FRANK; GU, FAN
To: INTERFACE BIOLOGICS INC.
Reel/Frame 030190/0018 →
Continuity (2)
Provisional Application 61125459 · Apr 25, 2008
Related Publication 20100034862A1 · Feb 11, 2010